Tuesday, January 31, 2023

Vana Care, an innovative South Australian disability support service, has launched a new model of support

Created by two friends in March 2021, the vision for Vana Care was to bring about an improved level of support and experience for those with a disability. The team behind this passion project is dedicated to providing clients with choice, control, and variety when aligning with their National Disability Insurance Scheme (NDIS) goals.

Created by two friends in March 2021, the vision for Vana Care was to bring about an improved level of support and experience for those with a disability. The team behind this passion project is dedicated to providing clients with choice, control, and variety when aligning with their National Disability Insurance Scheme (NDIS) goals.

Vana Care's holistic approach to supporting individuals through their NDIS journey has snowballed since its inception 1 year and 10 months ago. From humble beginnings, they have expanded across South Australia and built an impressive team of dedicated people committed to making a meaningful difference in people's lives.

Vana Care is a reputable provider of support services for individuals with disabilities. They offer a range of services, including Disability Support, Support Worker, In Home Support, Community Access, and Supported Independent Living (SIL). The company's team of professionals, including Support Workers and Disability Support Workers, are highly trained and dedicated to helping clients achieve their goals and live as independently as possible. In addition, Vana Care also offers Community Access Support Worker, NDIS and NDIS Worker services which assist clients in accessing their local community and participating in activities of their choosing. The overall goal of the company is to empower clients to live their best lives and to be active members of their communities.

The founders of Vana Care believe that having choice, control, and variety is essential when experiencing life as best as possible under one's NDIS plan. Through collaboration between different support providers, they can deliver services tailored specifically to each individual's needs while creating positive outcomes that assist them in leading fulfilling lives.

At Vana Care, client feedback is at the core of what drives them forward each day. They take the time to understand each person's unique goals and aspirations through regular communication and comprehensive mapping of mental health issues where required - something not often found within the industry today.

According to the senior manager at Vana Care, Rhys Johnson: "We believe that everyone should have access to high-quality service regardless of ability or financial situation."

Johnson  added: "At Vana Care, we strive daily to ensure our clients feel empowered, connected, and respected while still meeting their specific care needs."

Vana Care has quickly become well-known amongst regional communities across South Australia due to its commitment to creating an inclusive environment for those living with a disability – something not often seen within traditional disability service models. This inclusive approach also applies internally within their organization as more than 70% of its employees have personal experience with disability, whether it be through a loved one or through their own experience. This gives them a deep understanding and empathy for the individuals they serve, as they have been in similar situations themselves. This level of lived experience among the staff sets Vana Care apart and allows them to provide exceptional care and support for those with disabilities.

As part of the launch event held today in Adelaide CBD, Vana Care's staff members were joined by family members, advocates from the disability sector, and media representatives who had come out in force to show their support for this ground-breaking initiative. The response was overwhelming, with many attendees commenting on how excited they were about seeing such a positive change within the industry after so many years of uncertainty around access to services for those with disabilities.

Final Thought

Vana Care ends a long era where disabled individuals have felt excluded or neglected when seeking essential services – but through providing meaningful choice, control, and variety, they can now look forward to experiencing life differently, knowing they have access to quality supports that make a real difference in their day-to-day lives.

For more information visit  https://vanacare.com.au.

Media Contact
Company Name: Vana Care
Email:Send Email
Phone: (08) 8986 1991
Country: Australia
Website: https://vanacare.com.au

Electric Car Market is Booming Worldwide | Tesla, Tata Motors, Audi

Electric Car Market is Booming Worldwide | Tesla, Tata Motors, Audi
Electric Car Market
AMA Research released the latest study on Global Electric Car Market Growth Outlook 2022-2028 provides an opportunity to better understand details about fundamental restructuring and growth prognosis in Electric Car Market. This study offers current relevant facts and correlations and elaborates long-term, sustainable strategic and operative suggestions taken up by leading and emerging manufacturers

AMA Research released the latest study on Global Electric Car Market Growth Outlook 2022-2028 provides an opportunity to better understand details about fundamental restructuring and growth prognosis in Electric Car Market. This study offers current relevant facts and correlations and elaborates long-term, sustainable strategic and operative suggestions taken up by leading and emerging manufacturers. The sector faces an unprecedented change with regard to the far-reaching effects that it will have on the industry and its users and how it has been factored into the market trajectory and growth cycle of players such as Tesla (United States), Tata Motors (India), Audi (Germany), Mercedes (Germany), Jaguar (United Kingdom), Hyundai (South Korea), MG Motors (Birmingham), Mahindra (India), BMW (Germany), Volkswagen AG (Germany).

Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/75148-global-electric-car-market#utm_source=ABNewswire/Rahul

Scope of the Report of Electric Car The electric car is also known as the battery-electric car. This is automotive that is impelled by at least one electric engine, utilizing energy put away in batteries. Electric vehicles are quieter and have no fumes emanating, and lower outflows overall. Electric vehicles are less expensive than identical ICE vehicles, because of lower powering and upkeep costs. Charging an electric car should be possible at an assortment of charging stations and these stations can be introduced in public areas. Electric cars are a kind of electric vehicle (EV) that has a battery-powered battery pack locally available that can be charged from the electric matrix, and the power put away on the vehicle is the main source that drives the wheels for impetus. The expression "electric cars" by and large alludes to expressway skilled cars, yet there are likewise low-speed electric vehicles with limits as far as weight, force, and greatest speed that are permitted to go on open streets.

The titled segments and sub-section of the market are illuminated below:by Type (Battery Electric Car, Hybrid Electric Car, Plug-In Hybrid Electric Car), Application (Commercial Use, Household Use), Speed (125 MPH), Pricing (Mid-Priced, Semi-Luxury, Luxury), Car Type (Passenger Cars, Commercial Cars), Drive (All-Wheel Drive, Front-Wheel Drive, Rear Wheel Drive), Charging (Normal Charging, Super Charging)

Market Trends: Different countries shifting from normal vehicles to electric vehicles to protect the environment and due to scare of oil resourcesGrowing demand for the electric car in the emerging countries

Opportunities: The government are taking initiatives to promote electric vehicle Increase research and development activities by existing and new organizations in electric cars

Market Drivers: Growing demand for low emission commuting long-range supporting electric cars Increase in technological advancements regarding batteries and rise in production of batteries on a mass scale in large volumes Decrease in cost of Electric Vehicle batteries

 

Latest Market Insights: On 3 September 2021, YASA a British electric motor startup with a revolutionary “axial-flux” motor, was acquired by Mercedes-Benz. YASA will now develop ultra-high-performance electric motors for Mercedes-Benz’s AMG.EA electric-only platform. It will stay in the U.K. as a fully owned subsidiary, serving both Mercedes-Benz and existing customers like Ferrari.

 

On 22 September 2021, German luxury car manufacturer Audi, added two fully electric four-door coupes – the Audi e-Tron GT and the Audi RS e-Tron GT – to its range of electric vehicles in India. These are the first fully electric sports cars from Audi and these vehicles are designed to outperform

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Have Any Questions Regarding Global Electric Car Market Report, Ask Our Experts@ https://www.advancemarketanalytics.com/enquiry-before-buy/75148-global-electric-car-market#utm_source=ABNewswire/Rahul

Strategic Points Covered in Table of Content of Global Electric Car Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Electric Car market

Chapter 2: Exclusive Summary – the basic information of the Electric Car Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Electric Car

Chapter 4: Presenting the Electric Car Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Electric Car market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2027)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

finally, Electric Car Market is a valuable source of guidance for individuals and companies.

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/75148-global-electric-car-market#utm_source=ABNewswire/Rahul

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.

Media Contact
Company Name: AMA Research & Media LLP
Contact Person: Praveen Kumar (PR & Marketing Manager)
Email:Send Email
Phone: +1(201) 7937323, +1(201) 7937193
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: https://www.advancemarketanalytics.com/

Acanthamoeba Keratitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight

Acanthamoeba Keratitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight
The Acanthamoeba Keratitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acanthamoeba Keratitis pipeline products will significantly revolutionize the Acanthamoeba Keratitis market dynamics.

DelveInsight’s “Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Acanthamoeba Keratitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Acanthamoeba Keratitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acanthamoeba Keratitis Market Insights

 

Acanthamoeba Keratitis Overview

Acanthamoeba Keratitis (AK) is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living amoeba called Acanthamoeba. Two of the eight known species of Acanthamoeba, A. castellanii and A polyphaga, are responsible for most infections. The organism infects the transparent outer covering of the eye called the cornea. The protozoan is ubiquitous in nature and can be found in waterbodies (for example, lakes and oceans), soil, air, cooling towers, heating, ventilating, and air conditioning (HVAC) systems, and sewage systems.

 

Some of the key facts of the Acanthamoeba Keratitis Market Report: 

  • The Acanthamoeba Keratitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the US Centers for Disease Control and Prevention (CDC), the majority of those who are affected by Acanthamoeba Keratitis wear contact lenses. An estimated 85% of cases in the US involve people who wear contact lenses
  • According to Lacerda & Lira, study, sight-threatening AK is most commonly found in young soft contact lens (CL)wearers and agricultural workers, though it can also be present in non-CL wearers
  • Key Acanthamoeba Keratitis Companies: SIFI, and others
  • Key Acanthamoeba Keratitis Therapies: Akantior, and others
  • The Acanthamoeba Keratitis epidemiology based on gender analyzed that Acanthamoeba Keratitis affects male and female equally

 

Get a Free sample for the Acanthamoeba Keratitis Market Report -

https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

 

Key benefits of the Acanthamoeba Keratitis Market report:

  1. Acanthamoeba Keratitis market report covers a descriptive overview and comprehensive insight of the Acanthamoeba Keratitis Epidemiology and Acanthamoeba Keratitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Acanthamoeba Keratitis market report provides insights on the current and emerging therapies.
  3. Acanthamoeba Keratitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Acanthamoeba Keratitis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acanthamoeba Keratitis market.

 

Download the report to understand which factors are driving Acanthamoeba Keratitis epidemiology trends @ Acanthamoeba Keratitis Epidemiological Insights 

 

Acanthamoeba Keratitis Market  

The dynamics of the Acanthamoeba Keratitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Acanthamoeba Keratitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Acanthamoeba Keratitis Epidemiology Segmentation:

The Acanthamoeba Keratitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Acanthamoeba Keratitis
  • Prevalent Cases of Acanthamoeba Keratitis by severity
  • Gender-specific Prevalence of Acanthamoeba Keratitis
  • Diagnosed Cases of Episodic and Chronic Acanthamoeba Keratitis

 

Acanthamoeba Keratitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acanthamoeba Keratitis market or expected to get launched during the study period. The analysis covers Acanthamoeba Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acanthamoeba Keratitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Acanthamoeba Keratitis market share @ Acanthamoeba Keratitis market forecast 

 

Acanthamoeba Keratitis Therapies and Key Companies

  • Akantior: SIFI

 

Scope of the Acanthamoeba Keratitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Acanthamoeba Keratitis Companies: SIFI, and others
  • Key Acanthamoeba Keratitis Therapies: Akantior, and others
  • Acanthamoeba Keratitis Therapeutic Assessment: Acanthamoeba Keratitis current marketed and Acanthamoeba Keratitis emerging therapies
  • Acanthamoeba Keratitis Market Dynamics: Acanthamoeba Keratitis market drivers and Acanthamoeba Keratitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Acanthamoeba Keratitis Unmet Needs, KOL’s views, Analyst’s views, Acanthamoeba Keratitis Market Access and Reimbursement 

 

Table of Contents 

1. Acanthamoeba Keratitis Market Report Introduction

2. Executive Summary for Acanthamoeba Keratitis

3. SWOT analysis of Acanthamoeba Keratitis

4. Acanthamoeba Keratitis Patient Share (%) Overview at a Glance

5. Acanthamoeba Keratitis Market Overview at a Glance

6. Acanthamoeba Keratitis Disease Background and Overview

7. Acanthamoeba Keratitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Acanthamoeba Keratitis 

9. Acanthamoeba Keratitis Current Treatment and Medical Practices

10. Acanthamoeba Keratitis Unmet Needs

11. Acanthamoeba Keratitis Emerging Therapies

12. Acanthamoeba Keratitis Market Outlook

13. Country-Wise Acanthamoeba Keratitis Market Analysis (2019–2032)

14. Acanthamoeba Keratitis Market Access and Reimbursement of Therapies

15. Acanthamoeba Keratitis Market Drivers

16. Acanthamoeba Keratitis Market Barriers

17.  Acanthamoeba Keratitis Appendix

18. Acanthamoeba Keratitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Acanthamoeba Keratitis treatment, visit @ Acanthamoeba Keratitis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Anaphylaxis Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - AstraZeneca, Aquestive Therapeutics The Anaphylaxis market is expected to surge due to the disease's incre

Anaphylaxis Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - AstraZeneca, Aquestive Therapeutics The Anaphylaxis market is expected to surge due to the disease's incre
The Anaphylaxis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anaphylaxis pipeline products will significantly revolutionize the Anaphylaxis market dynamics.

DelveInsight’s “Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Anaphylaxis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Anaphylaxis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Anaphylaxis Market Insights

 

Anaphylaxis Overview

Anaphylaxis is an acute, potentially life-threatening, generalized, or systemic allergic reaction that is mediated by the degranulation of mast cells and basophils.

The condition usually develops suddenly and gets worse very quickly. The symptoms include feeling lightheaded or faint, breathing difficulties – such as fast, shallow breathing, wheezing, fast heartbeat, clammy skin, confusion and anxiety, collapsing or losing consciousness. There may also be other allergy symptoms, including an itchy, raised rash (hives), feeling or being sick, swelling (angioedema) or stomach pain.

 

Some of the key facts of the Anaphylaxis Market Report: 

  • The Anaphylaxis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Yu et al., conducted a study titled “The Epidemiology of Anaphylaxis”, wherein the lifetime prevalence of anaphylaxis was estimated at 0.05–2% in the USA and approximately 3% in Europe
  • A report from Manchester UK, of patients presenting to paramedics and first aides estimated 0.2% of emergency cases due to anaphylaxis
  • As per Tanno et al., European data have indicated incidence rates for all-cause anaphylaxis ranging from 1.5 to 7.9 per 100,000 person/year, with an estimate that 0.3% (95% CI 0.1–0.5) of the population will experience anaphylaxis at some point during their lifetime. It is also estimated that 1 in every 3000 inpatients in US hospitals suffer from an anaphylactic reaction
  • Key Anaphylaxis Companies: AstraZeneca, Aquestive Therapeutics, and others
  • Key Anaphylaxis Therapies: Acalabrutinib, AQST-108, AQST-109, and others
  • The Anaphylaxis epidemiology based on gender analyzed that Anaphylaxis affects equally both females and males

 

Get a Free sample for the Anaphylaxis Market Report -

https://www.delveinsight.com/sample-request/anaphylaxis-market 

 

Key benefits of the Anaphylaxis Market report:

  1. Anaphylaxis market report covers a descriptive overview and comprehensive insight of the Anaphylaxis Epidemiology and Anaphylaxis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Anaphylaxis market report provides insights on the current and emerging therapies.
  3. Anaphylaxis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Anaphylaxis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Anaphylaxis market.

 

Download the report to understand which factors are driving Anaphylaxis epidemiology trends @ Anaphylaxis Epidemiological Insights 

 

Anaphylaxis Market  

The dynamics of the Anaphylaxis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Anaphylaxis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Anaphylaxis Epidemiology Segmentation:

The Anaphylaxis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Anaphylaxis
  • Prevalent Cases of Anaphylaxis by severity
  • Gender-specific Prevalence of Anaphylaxis
  • Diagnosed Cases of Episodic and Chronic Anaphylaxis

 

Anaphylaxis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Anaphylaxis market or expected to get launched during the study period. The analysis covers Anaphylaxis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Anaphylaxis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Anaphylaxis market share @ Anaphylaxis market forecast 

 

Anaphylaxis Therapies and Key Companies

  • Acalabrutinib: AstraZeneca
  • AQST-108: Aquestive Therapeutics
  • AQST-109: Aquestive Therapeutics

 

Anaphylaxis Market Strengths

  • One of the major strengths of this market is the increasing patient pool, awareness and support for the disease which will drive the market in the long run
  • Several organizations such as World Allergy Organization, Anaphylaxis campaign are actively working to provide information and awareness of Anaphylaxis

 

Scope of the Anaphylaxis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Anaphylaxis Companies: AstraZeneca, Aquestive Therapeutics, and others
  • Key Anaphylaxis Therapies: Acalabrutinib, AQST-108, AQST-109, and others
  • Anaphylaxis Therapeutic Assessment: Anaphylaxis current marketed and Anaphylaxis emerging therapies
  • Anaphylaxis Market Dynamics: Anaphylaxis market drivers and Anaphylaxis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Anaphylaxis Unmet Needs, KOL’s views, Analyst’s views, Anaphylaxis Market Access and Reimbursement 

 

Anaphylaxis Market opportunities

  • Awareness about allergy tests is expected to prevent the anaphylaxis condition. Moreover, early diagnosis of allergic reactions as a result of advanced tests is likely to drive the anaphylaxis market. Approvals of Epinephrine auto injectors and other drugs are likely to boost the anaphylaxis treatment market
  • Thriving research and development to understand the diversity of the disease might improve the diagnosis of Anaphylaxis, thereby resulting in a lucrative market opportunity

 

Table of Contents 

1. Anaphylaxis Market Report Introduction

2. Executive Summary for Anaphylaxis

3. SWOT analysis of Anaphylaxis

4. Anaphylaxis Patient Share (%) Overview at a Glance

5. Anaphylaxis Market Overview at a Glance

6. Anaphylaxis Disease Background and Overview

7. Anaphylaxis Epidemiology and Patient Population

8. Country-Specific Patient Population of Anaphylaxis 

9. Anaphylaxis Current Treatment and Medical Practices

10. Anaphylaxis Unmet Needs

11. Anaphylaxis Emerging Therapies

12. Anaphylaxis Market Outlook

13. Country-Wise Anaphylaxis Market Analysis (2019–2032)

14. Anaphylaxis Market Access and Reimbursement of Therapies

15. Anaphylaxis Market Drivers

16. Anaphylaxis Market Barriers

17.  Anaphylaxis Appendix

18. Anaphylaxis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Anaphylaxis treatment, visit @ Anaphylaxis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Cancer Anorexia Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) - Evaluated by DelveInsight | Key Companies - Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals

Cancer Anorexia Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) - Evaluated by DelveInsight | Key Companies - Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals
The Cancer Anorexia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Anorexia pipeline products will significantly revolutionize the Cancer Anorexia market dynamics.

DelveInsight’s “Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cancer Anorexia, historical and forecasted epidemiology as well as the Cancer Anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Cancer Anorexia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Cancer Anorexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Anorexia Market Insights

 

Cancer Anorexia Overview

Anorexia is a common symptom in people with cancer and a component of the cancer anorexia-cachexia syndrome (CACS).It is the lack or loss of appetite or desire to eat leading to reduced intake; however, it alone does not account for the complex alterations that characterize the CACS. The anorexia and accompanying weight loss may occur at any stage of illness with variable severity, and it may be related to several causal factors.

 

Some of the key facts of the Cancer Anorexia Market Report: 

  • The Cancer Anorexia market size was valued at USD 309.50 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total incident population of anorexia by cancer types in the seven major markets was estimated to be 747,677 in 2021
  • The total incident population of anorexia by cancer types in the United States was 269,338 in2021
  • Anorexia is one of the top three common symptoms in patients with cancer at the end of life
  • As per the studies of Muscaritoli et al., the prevalence of malnutrition in oncology (PreMiO) study which found that over 40% of cancer patients were experiencing anorexia, as reported in the VAS and FAACT questionnaire. Furthermore, more than 70% of pancreatic and gastroesophageal cancer patients, more than 60% of liver, colorectal, and GItract, and more than 40% of lung, head, and neck, and genitourinary cancer patients could be classified as cachectic, based on BMI and weight loss
  • According to the article published by Currow, up to 70% of patients with advanced cancer, including those with advanced NSCLC, experience cancer anorexia/cachexia syndrome, which by definition, cannot be reversed with nutritional support alone
  • Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others
  • Key Cancer Anorexia Therapies: Adlumiz, ART27.13, NGM120, and others
  • The Cancer Anorexia epidemiology based on gender analyzed that Cancer Anorexia occurs in both men and women

 

Get a Free sample for the Cancer Anorexia Market Report -

https://www.delveinsight.com/sample-request/cancer-anorexia-market

 

Key benefits of the Cancer Anorexia Market report:

  1. Cancer Anorexia market report covers a descriptive overview and comprehensive insight of the Cancer Anorexia Epidemiology and Cancer Anorexia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Cancer Anorexia market report provides insights on the current and emerging therapies.
  3. Cancer Anorexia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Cancer Anorexia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Cancer Anorexia market.

 

Download the report to understand which factors are driving Cancer Anorexia epidemiology trends @ Cancer Anorexia Epidemiological Insights 

 

Cancer Anorexia Market  

The dynamics of the Cancer Anorexia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“According to the estimates, the highest market size of Cancer Anorexia was found in theUnitedStates and the least was in Spain across the 7MM. Besides, the upcoming therapies of CancerAnorexia are expected to combat the current unmet needs faced by the patients with CancerAnorexia and add to the overall growth of the Cancer Anorexia market size”

 

Cancer Anorexia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cancer Anorexia Epidemiology Segmentation:

The Cancer Anorexia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Cancer Anorexia
  • Prevalent Cases of Cancer Anorexia by severity
  • Gender-specific Prevalence of Cancer Anorexia
  • Diagnosed Cases of Episodic and Chronic Cancer Anorexia

 

Cancer Anorexia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Anorexia market or expected to get launched during the study period. The analysis covers Cancer Anorexia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Anorexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Cancer Anorexia market share @ Cancer Anorexia market forecast 

 

Cancer Anorexia Therapies and Key Companies

  • Adlumiz: Helsinn Healthcare
  • ART27.13: Artelo Biosciences
  • NGM120: NGM Biopharmaceuticals

 

Cancer Anorexia Market Drivers

  • An increasing population of cancer patients with anorexia in the 7MM
  • Scope of upcoming therapies
  • Opportunity for novel treatments
  • Presence of effective disease scoring system

 

Scope of the Cancer Anorexia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Cancer Anorexia Companies: Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, and others
  • Key Cancer Anorexia Therapies: Adlumiz, ART27.13, NGM120, and others
  • Cancer Anorexia Therapeutic Assessment: Cancer Anorexia current marketed and Cancer Anorexia emerging therapies
  • Cancer Anorexia Market Dynamics: Cancer Anorexia market drivers and Cancer Anorexia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Cancer Anorexia Unmet Needs, KOL’s views, Analyst’s views, Cancer Anorexia Market Access and Reimbursement 

 

Cancer Anorexia Market Barriers

  • Disease burden and impact on the quality of life
  • Lack of knowledge about the condition
  • The high mortality rate in cancer patients due to anorexia

 

Table of Contents 

1. Cancer Anorexia Market Report Introduction

2. Executive Summary for Cancer Anorexia

3. SWOT analysis of Cancer Anorexia

4. Cancer Anorexia Patient Share (%) Overview at a Glance

5. Cancer Anorexia Market Overview at a Glance

6. Cancer Anorexia Disease Background and Overview

7. Cancer Anorexia Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Anorexia 

9. Cancer Anorexia Current Treatment and Medical Practices

10. Cancer Anorexia Unmet Needs

11. Cancer Anorexia Emerging Therapies

12. Cancer Anorexia Market Outlook

13. Country-Wise Cancer Anorexia Market Analysis (2019–2032)

14. Cancer Anorexia Market Access and Reimbursement of Therapies

15. Cancer Anorexia Market Drivers

16. Cancer Anorexia Market Barriers

17.  Cancer Anorexia Appendix

18. Cancer Anorexia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Cancer Anorexia treatment, visit @ Cancer Anorexia Medications 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Prediabetes Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Valbiotis, Ingredia, Novo Nordisk, Advent Health

Prediabetes Market to Grow at a Substantial Growth Rate During the Forecast Period  (2022-2032) -  DelveInsight | Key Companies - Valbiotis, Ingredia, Novo Nordisk, Advent Health
The Prediabetes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prediabetes pipeline products will significantly revolutionize the Prediabetes market dynamics.

DelveInsight’s “Prediabetes Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prediabetes, historical and forecasted epidemiology as well as the Prediabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Prediabetes market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Prediabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prediabetes Market Insights

 

Prediabetes Overview

According to the Centers for Disease Control and Prevention (CDC), prediabetes is a serious health condition where blood-sugar levels are higher than normal, but not high enough to get diagnosed easily as type 2 diabetes. Prediabetes, is also commonly referred to as borderline diabetes, which is a metabolic condition and growing global problem closely related to obesity.

 

Some of the key facts of the Prediabetes Market Report: 

  • The Prediabetes market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the CDC, prediabetes had a prevalence of 96 million among adults in the US in 2019, which accounted for 38% of the entire US adult population. Of these cases, 26.4 million people aged 65 years or older, signifying a 48.8% prevalence in that particular age group
  • As per Hostalek, prediabetes progresses to type-2 diabetes in approximately 25% of subjects within 3–5 years, and as many as 70% of individuals with prediabetes will develop overt diabetes within their lifetime
  • Key Prediabetes Companies: Valbiotis, Ingredia, Novo Nordisk, Advent Health, and others
  • Key Prediabetes Therapies: Totum-63, Pep2Dia, Semaglutide 2.4 mg, ABA, and others
  • The Prediabetes epidemiology based on gender analyzed that Prediabetes is slightly more common in males than in females

 

Get a Free sample for the Prediabetes Market Report -

https://www.delveinsight.com/sample-request/prediabetes-market

 

Key benefits of the Prediabetes Market report:

  1. Prediabetes market report covers a descriptive overview and comprehensive insight of the Prediabetes Epidemiology and Prediabetes market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Prediabetes market report provides insights on the current and emerging therapies.
  3. Prediabetes market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Prediabetes market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Prediabetes market.

 

Download the report to understand which factors are driving Prediabetes epidemiology trends @ Prediabetes Epidemiological Insights 

 

Prediabetes Market  

The dynamics of the Prediabetes market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Prediabetes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Prediabetes Epidemiology Segmentation:

The Prediabetes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Prediabetes
  • Prevalent Cases of Prediabetes by severity
  • Gender-specific Prevalence of Prediabetes
  • Diagnosed Cases of Episodic and Chronic Prediabetes

 

Prediabetes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prediabetes market or expected to get launched during the study period. The analysis covers Prediabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prediabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Prediabetes market share @ Prediabetes market forecast 

 

Prediabetes Therapies and Key Companies

  • Totum-63: Valbiotis
  • Pep2Dia: Ingredia
  • Semaglutide 2.4 mg: Novo Nordisk
  • ABA: AdventHealth

 

Prediabetes Market Drivers

  • Growing Awareness among prediabetic patients, leading to increase in diagnosed patient pool
  • Growth in research and developmental activities about this indication can give good returns in future

 

Scope of the Prediabetes Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Prediabetes Companies: Valbiotis, Ingredia, Novo Nordisk, Advent Health, and others
  • Key Prediabetes Therapies: Totum-63, Pep2Dia, Semaglutide 2.4 mg, ABA, and others
  • Prediabetes Therapeutic Assessment: Prediabetes current marketed and Prediabetes emerging therapies
  • Prediabetes Market Dynamics: Prediabetes market drivers and Prediabetes market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Prediabetes Unmet Needs, KOL’s views, Analyst’s views, Prediabetes Market Access and Reimbursement 

 

Prediabetes Market Opportunities

  • There is no approved treatment for Prediabetes which creates an opportunity for new players
  • The current treatment options are off-label therapies for treating patients with Prediabetes, which open a platform of new therapies to boost the market of the indication

 

Table of Contents 

1. Prediabetes Market Report Introduction

2. Executive Summary for Prediabetes

3. SWOT analysis of Prediabetes

4. Prediabetes Patient Share (%) Overview at a Glance

5. Prediabetes Market Overview at a Glance

6. Prediabetes Disease Background and Overview

7. Prediabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Prediabetes 

9. Prediabetes Current Treatment and Medical Practices

10. Prediabetes Unmet Needs

11. Prediabetes Emerging Therapies

12. Prediabetes Market Outlook

13. Country-Wise Prediabetes Market Analysis (2019–2032)

14. Prediabetes Market Access and Reimbursement of Therapies

15. Prediabetes Market Drivers

16. Prediabetes Market Barriers

17.  Prediabetes Appendix

18. Prediabetes Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Prediabetes treatment, visit @ Prediabetes Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Retail Bank Loyalty Program Market to See Huge Growth by 2027 | Exchange Solutions, Customer Portfolios, TIBCO Software, Maritz

Retail Bank Loyalty Program Market to See Huge Growth by 2027 | Exchange Solutions, Customer Portfolios, TIBCO Software, Maritz
Retail Bank Loyalty Program
Retail Bank Loyalty Program Comprehensive Study by Application (Customer retention, Customer loyalty, Channel loyalty), Components (Solutions, Services), End users (Personal User, Business User), Program Type (Refer a friend, Reward program, Choice rewards, Others) Players and Region - Global Market Outlook to 2027

Advance Market Analytics published a new research publication on“Global Retail Bank Loyalty Program Market Insights, to 2027” with 232 pages and enriched with self-explained Tables and charts in presentable format. In the study, you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market-associated stakeholders. The growth of the Retail Bank Loyalty Program market was mainly driven by the increasing R&D spending across the world.

Major players profiled in the study are:

Maritz (United States), FIS Corporate (United States), IBM (United States), Aimia (Canada), TIBCO Software (United States), Hitachi-solutions (Japan), Oracle Corporation (United States), Comarch (Poland), Loyalty Lab (Netherlands), Exchange Solutions (Canada), Bpm’ online (United States), Customer Portfolios (United States)

Get Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/76442-global-retail-bank-loyalty-program-market#utm_source=AbNewsVinay

Scope of the Report of Retail Bank Loyalty Program

The loyalty programs are the marketing strategies which are designed to encourage customers to use the services of a business. A retail bank loyalty program is one of the important tools for retail banking industry. There is rapid growth of banks which is making a competitive situation in industry. Hence, the marketing strategies for retaining customers are becoming diversified including loyalty program strategy. The strategy is also being considered as an important revenue driving tool. It offers various number of loyalty programs but they are commoditized.

The Global Retail Bank Loyalty Program Market segments and Market Data Break Down are illuminated below:

by Application (Customer retention, Customer loyalty, Channel loyalty), Components (Solutions, Services), End users (Personal User, Business User), Program Type (Refer a friend, Reward program, Choice rewards, Others)

Market Opportunities:

  • Personalization in Loyalty Programs is Leading to Adoption by Customers
  • Increasing Importance of Customer Insights to Predict Customer Intents

Market Drivers:

  • Increasing Emphasis on Marketing Strategies in Banking Sector
  • Increasing Competition in the Industry

Market Trend:

  • Adoption of Analytical Tools for Offering Customized Reward Programs

What can be explored with the Retail Bank Loyalty Program Market Study?

  • Gain Market Understanding
  • Identify Growth Opportunities
  • Analyze and Measure the Global Retail Bank Loyalty Program Market by Identifying Investment across various Industry Verticals
  • Understand the Trends that will drive Future Changes in Retail Bank Loyalty Program
  • Understand the Competitive Scenarios

-          Track Right Markets

-          Identify the Right Verticals

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Have Any Questions Regarding Global Retail Bank Loyalty Program Market Report, Ask Our Experts@ https://www.advancemarketanalytics.com/enquiry-before-buy/76442-global-retail-bank-loyalty-program-market#utm_source=AbNewsVinay

Strategic Points Covered in Table of Content of Global Retail Bank Loyalty Program Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Retail Bank Loyalty Program market

Chapter 2: Exclusive Summary – the basic information of the Retail Bank Loyalty Program Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Retail Bank Loyalty Program

Chapter 4: Presenting the Retail Bank Loyalty Program Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2016-2021

Chapter 6: Evaluating the leading manufacturers of the Retail Bank Loyalty Program market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2022-2027)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Retail Bank Loyalty Program Market is a valuable source of guidance for individuals and companies.

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/buy-now?format=1&report=76442#utm_source=AbNewsVinay

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.

Media Contact
Company Name: AMA Research & Media LLP
Contact Person: Praveen Kumar (PR & Marketing Manager)
Email:Send Email
Phone: +1(201) 7937323, +1(201) 7937193
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: https://www.advancemarketanalytics.com/

Indian Fertilizer Market 2023-2028: Industry Overview, Price Analysis, Drivers, Demand and Forecast Report

Indian Fertilizer Market 2023-2028: Industry Overview, Price Analysis, Drivers, Demand and Forecast Report
Indian Fertilizer Market
The Indian Fertilizer market is driven by rapid urbanization and the decreasing availability of arable land.

How big is the fertilizer industry in India?

IMARC Group’s latest research report, titled “Indian Fertilizer Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” The Indian fertilizer market size reached INR 898.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach INR 1,188.3 Billion by 2028, exhibiting a growth rate (CAGR) of 4.85% during 2023-2028.


Fertilizer refers to a natural or artificial substance added to the soil to promote the healthy growth and productivity of farm crops. It is produced using livestock manure, municipal sludge, industrial waste and carbon-based agricultural waste. It comprises several nutrients and microbes, including potassium, nitrogen, and phosphorus, that are essential for efficient plant growth and to maintain the water retention capacity and natural fertility of the soil. As a result, it plays a significant place in the success of India's green revolution and self-reliance in food-grain production. Some of the commonly available fertilizer variants in India include phosphatic, nitrogenous, potash and micronutrient.


Get Free Sample Copy of Report at –
 https://www.imarcgroup.com/indian-fertilizer-market/requestsample


What is the demand for fertilizers in India?

The escalating need for sustainable food production majorly drives the market in India. This is attributed to the growing population along with the increasing popularity of agriculture on a commercial level across the country. In recent years, numerous initiatives have been undertaken by the government in order to improve credit availability and investments, increasing the provision of quality inputs and promoting infrastructure development, further boosting the market growth. Moreover, continuous product innovations, such as the launch of nano-fertilizers (NFs) that aid in maintaining flat green grounds and fields, is creating a positive market outlook.


Browse Full Report With TOC:
 https://www.imarcgroup.com/indian-fertilizer-market


Indian Fertilizer Industry Growth Analysis:

Besides this, rising number of government and non-government awareness campaigns for educating farmers regarding the benefits of fertilizers. For instance, various promotions are done through radio, television and customized rural workshops to enhance the consumption of fertilizers in the country is significantly supporting the Indian fertilizer market. Furthermore, continuous technological advancements and the widespread adoption of advanced farming techniques are contributing to the growth of the market. Apart from this, key players are heavily investing in extensive research and development (R&D) activities for introducing bio-fertilizers due to the growing environmental consciousness among individuals is propelling the growth. Other factors driving the market include increasing awareness and widespread adoption of organic farming practices and declining arable land.


Do you know more information, Contact to our analyst at– 
https://www.imarcgroup.com/request?type=report&id=1044&flag=C


Key Market Segmentation:


Biggest Suppliers in Indian Fertilizer Industry
 :

  • Coromandel International Limited
  • Deepak Fertilizers and Petrochemicals Corporation Limited
  • Fertilizers And Chemicals Travancore Limited (FACT)
  • Gujarat Narmada Valley Fertilizers & Chemicals Limited (GNFC)
  • Gujarat State Fertilizers & Chemicals Limited (GSFC)
  • Hindustan Fertilizer Corporation Limited (HFCL)
  • Indian Farmers Fertilizer Cooperative Limited (IFFCO)
  • Krishak Bharati Cooperative Limited (KRIBHCO)
  • MADRAS FERTILIZERS LIMITED


Breakup by Product Type:

  • Chemical Fertilizers
  • Biofertilizers


Breakup by Segment:

  • Complex Fertilizers
  • DAP
  • MOP
  • Urea
  • SSP
  • Others


Breakup by Formulation:

  • Liquid
  • Dry


Breakup by Application:

  • Farming
    • Grains and Cereals
    • Oilseeds
    • Fruits and Vegetables
    • Others
  • Gardening


Breakup by Region:

  • East India
  • North India
  • South India
  • West India


Browse More Research Reports:


Who we are:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email:Send Email
Phone: +1-631-791-1145
Address:30 N Gould St Ste R
City: Sheridan
State: WY
Country: United States
Website: https://www.imarcgroup.com

Respiratory Syncytial Virus Pipeline Insight and Clinical Trial Analysis Featuring 50+ Key Companies by DelveInsight

Respiratory Syncytial Virus Pipeline Insight and Clinical Trial Analysis Featuring 50+ Key Companies by DelveInsight

DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Respiratory Syncytial Virus pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Respiratory Syncytial Virus NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Respiratory Syncytial Virus Pipeline Report

 

  • DelveInsight's analysis depicts a robust Respiratory Syncytial Virus Infection Pipeline with 50+ active players in the domain working on 50+ pipeline therapies.

 

  • The leading Respiratory Syncytial Virus infection Companies includes Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others are under different phases of clinical trials for Respiratory Syncytial Virus.

 

  • Promising Respiratory Syncytial Virus Infection Pipeline therapies such as RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others are under different phases of clinical trials for Respiratory Syncytial Virus (RSV).

 

  • The Respiratory Syncytial Virus Infection companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus (RSV) R&D. The Respiratory Syncytial Virus Infection pipeline therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus (RSV).

 

To explore more information on the latest breakthroughs in the Respiratory Syncytial Virus Pipeline treatment landscape of the report, click here @ Respiratory Syncytial Virus Pipeline Outlook

 

Respiratory Syncytial Virus Overview

Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.

 

Recent Developments Activities in the Respiratory Syncytial Virus Treatment Landscape

  • Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV.
  • IVX-121 and IVX-A12 are the two vaccine candidates being developed by Icosavax, Inc. IVX-121 target Respiratory Syncytial Virus, a major cause of viral pneumonia for which no vaccine has been FDA approved.
  • ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. The Bill & Melinda Gates Foundation (BMGF) has supported the Prepare trial for ResVax through a grant of up to $89.1 million; BMGF continues to financially support our efforts to conduct certain follow-up analyses of the Phase III data.
  • In October 2020, Moderna, Inc., regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for delivery, entered Phase 1 development in 2019. Under the terms of the agreement, Merck will complete the Phase 1 study and transition the program to Moderna.
  • The development of V-306 Virometix offers a differentiated approach to RSV vaccine development. In Phase I clinical trial, V-306 demonstrated strong, durable, specific, and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease.
  • Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live-attenuated vaccine candidate, to protect infants and at-risk older adults from RSV. MV-012-968 is currently in a Phase IIa, randomized, double-blind, placebo-controlled challenge study designed to evaluate the safety and prophylactic efficacy of the Meissa vaccine against symptomatic RSV infection.

 

Request a sample and discover the recent advances in Respiratory Syncytial Virus Pipeline Ongoing Clinical Trial Analysis and Medications, click here @ Respiratory Syncytial Virus Pipeline Treatment Landscape

 

Respiratory Syncytial Virus Emerging Drugs

 

GSK3844766A: GlaxoSmithKline

This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory Syncytial Virus (RSV).

 

Nirsevimab (MEDI-8897): MedImmune

MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.

 

Sisunatovir: ReViral

Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations.

 

Respiratory Syncytial Virus Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

 

For further information, refer to the detailed Respiratory Syncytial Virus Unmet Needs, Respiratory Syncytial Virus Market Drivers, and Market Barriers, click here for Respiratory Syncytial Virus Ongoing Clinical Trial Analysis

 

Scope of the Respiratory Syncytial Virus Pipeline Report

  • Coverage- Global
  • Respiratory Syncytial Virus infection Companies- Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others.
  • Respiratory Syncytial Virus Infection Pipeline therapies- RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, and others.
  • Respiratory Syncytial Virus Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Respiratory Syncytial Virus Market Drivers and Respiratory Syncytial Virus Market Barriers, click here @ Respiratory Syncytial Virus Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Respiratory Syncytial Virus (RSV): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Respiratory Syncytial Virus (RSV) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. GSK3844766A: GlaxoSmithKline
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EDP 938: Enanta Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. mRNA-1345: Moderna Therapeutics
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. AR-201: Aridis Pharmaceuticals
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Respiratory Syncytial Virus (RSV) Key Companies
  23. Respiratory Syncytial Virus (RSV) Key Products
  24. Respiratory Syncytial Virus (RSV)- Unmet Needs
  25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
  26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
  27. Respiratory Syncytial Virus (RSV) Analyst Views
  28. Respiratory Syncytial Virus (RSV) Key Companies
  29. Appendix

 

Got Queries? Find out the related information on Respiratory Syncytial Virus Mergers and acquisitions, Respiratory Syncytial Virus Licensing Activities @ Respiratory Syncytial Virus Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services